Tag:
Allergan
Latest Headlines
Latest Headlines
Allergan to enlist new hires in R&D expansion
Allergan has ambitious plans to swell its ranks with the opening of a new R&D facility in the Garden State. The news comes amid a major push at Allergan to expand the use of Botox far beyond fixing facial wrinkles and to develop therapies for a variety of ailments.
FDA panel wants higher standard for obesity-treating devices
If the risk is higher, the reward should be, too. That's an FDA panel's opinion on anti-obesity devices seeking regulatory approval.
EndoSphere attracts $3.1M to fuel anti-obesity device launch
EndoSphere has nailed down $3.1 million in an as-yet unfinished Series B round. Plans call for using the cash to launch the company's Satisphere implantable anti-obesity device and fund subsequent post-marketing studies.
Allergan subpoenaed over Lap-Band obesity device
Allergan ($AGN) has been slapped with a subpoena from the inspector general of the Department of Health and Human Services regarding the company's Lap-Band obesity treatment device.
Allergan asks FDA for lucrative new Botox indication
Allergan has asked U.S. and European regulators to approve Botox to treat patients with garden-variety overactive bladder, citing two Phase III trials.
CMC, third-party manufacturing issues delay Map drug launch
CMC and manufacturing issues have tripped up Map Pharmaceuticals before it has even gotten out of the gate with Levadex.
California implant makers get FDA warnings
Two Murrieta, CA-based implant makers have been called on the carpet by the FDA for lacking quality control over their manufacturing or assembling processes.
Allergan wins injunction against Botox rival
Allergan won its injunction against a putative Botox competitor that had already grabbed 8% of the U.S. market after its first few weeks on sale. Germany's Merz Group was accused of appropriating Allergan's trade secrets in launching the alternative botulinum toxin drug Xeomin, and now faces 10 months off the cosmeceuticals market.
NICE holds out for more data on Botox for migraine
The U.K.'s cost-effectiveness watchdog is looking askance at Botox for chronic migraine. The National Institute for Health and Clinical Excellence has asked Allergan ( $AGN ) for more data to back up
Botox delivers for Allergan, Dr. Reddy's sees big profit increase during quarter
Another day, another round of earnings calls. Today's roundup includes Allergan, which received a boost from Botox, a widely known wrinkle-fighter that is now garnering approvals around the world for
